Continuing evidence that COVID-19 has influenced syphilis epidemiology in Rome

Alessandra Latini, ¹ Francesca Magri, ² Eugenia Giuliani, ³ Massimo Giuliani, ¹ Valentina Garelli, ¹ Martina Pontone, ⁴ Monica Salvi, ¹ Christof Stingone, ¹ Laura Gianserra, ¹ Fulvia Pimpinelli, ⁴ Anna Rita Buonomini, ¹ Aldo Morrone, ³ Maria Gabriella Donà ⁶, ¹ Mauro Zaccarelli ⁵

There are conflicting data on how COVID-19 has impacted STI epidemiology worldwide. In Rome, we observed a marked decrease in syphilis diagnoses during the first lockdown of spring 2020.² Extending our previous observations, we compared syphilis diagnoses (primary/ secondary/recent) during the whole of 2020 versus those of the previous 3 years (figure 1). While diagnoses by month were homogeneous in the prepandemic period (p for trend=0.40), 2020 showed a peak in June, a sharp and atypical decline in September, returning to the usual figures in November, when Rome was in 'soft' lockdown. We speculate that the increase in June might reflect: (1) visit postponement by patients who, despite being symptomatic, were reluctant to attend the hospital; (2) diagnoses of infections acquired during lockdown. Overall, syphilis diagnoses were 81 in 2020 compared with mean 106 (SE: 7) in 2017-2019 suggesting, to some extent, a reduction of at-risk sexual encounters in the pandemic period.

Handling editor Anna Maria Geretti

Twitter Massimo Giuliani @giumas3

Contributors Conceptualisation: AL, MZ. Data curation: EG, MG, MGD. Formal analysis: MGD,

Correspondence to Dr Maria Gabriella Donà, STI/ HIV Unit, San Gallicano Dermatological Institute IRCCS, Rome 00144, Italy; mariagabriella.dona@ifo.gov.it MZ. Investigation: AL, EG, FM, MG, MGD, MZ. Methodology: AL, MGD, MZ. Project administration: AL, MZ. Resources: VG, MP, MS, CS, LG, FP, ARB, AM. Supervision: AL, AM. Visualisation: AL, FM, EG, MGD, MZ. Writing—original draft: AL, FM, MGD, MZ. Writing—review and editing: EG, MG, VG, MP, MS, CS, LG, FP, ARB, AM.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Latini A, Magri F, Giuliani E, *et al.*Sex Transm Infect Epub ahead of print: [please include Day Month Year]. doi:10.1136/sextrans-2021-055250

Sex Transm Infect 2021;**0**:1. doi:10.1136/sextrans-2021-055250

ORCID iD

Maria Gabriella Donà http://orcid.org/0000-0003-3250-1726

REFERENCES

- 1 Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. accountability for the global health sector strategies 2016–2021: actions for impact, 2021. Geneva: World Health organization. Available: https://www.who.int/publications/i/item/ 9789240027077
- 2 Latini A, Magri F, Donà MG, et al. Is COVID-19 affecting the epidemiology of STIs? the experience of syphilis in Rome. Sex Transm Infect 2021;97:78.




Figure 1 Number of infectious syphilis (primary/secondary/recent syphilis), by month, diagnosed at the STI/HIV Unit of the San Gallicano Dermatological Institute (Rome, Italy), during the pandemic year (2020) and mean number (with range) of infectious syphilis, by month, diagnosed in the prepandemic period (2017–2019); the first strict lockdown and the second 'soft' lockdown (when Rome was in the low-risk yellow zone) are also indicated. (Created by the authors.)



¹STI/HIV Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy

²Department of Dermatology, University of Rome La Sapienza, Rome, Italy

³Scientific Direction, San Gallicano Dermatological Institute IRCCS, Rome, Italy

⁴Microbiology and Pathology Department, San Gallicano Dermatological Institute IRCCS, Rome, Italy ⁵Clinical Department, Lazzaro Spallanzani Hospital, Rome, Italy